FILTER
FILTERED INTERVIEW RESULTS
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."
Robert Poe
CEO, OLON RICERCA BIOSCIENCES
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."
Manni Kantipudi & Ramesh Subramanian
CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."
Chris Garabedian
CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."
Tom Wilson
GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."
Fabrice Panza
MANAGER GLOBAL COOL CHAIN SOLUTIONS, ETIHAD CARGO
"Etihad Cargo’s PharmaLife product has exponentially grown over the past year, and growth will trigger more physical ties between US and UAE."
James Sapirstein
CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”
Kendalle O’Connell
CEO AND PRESIDENT, MASSBIO
"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."
Arda Ural
AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES & WELLNESS, EY USA
"We are going to help the industry digitalize, prepare for the innovation deficit due to expiring patents and improve strategies that lead to better M&A opportunities."
David Schaffer
EXECUTIVE DIRECTOR, QB3
"The Bay Area offers a confluence of universities, investors and companies, and we are interested in strengthening bridges between these institutions to streamline the process of technology translation."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
